| Title |
Aromatase inhibitors with or without luteinizing hormone–releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature
|
|---|---|
| Published in |
Breast Cancer, February 2016
|
| DOI | 10.1007/s12282-016-0679-2 |
| Pubmed ID | |
| Authors |
Sayaka Kuba, Mayumi Ishida, Masahiro Oikawa, Yoshiaki Nakamura, Kosho Yamanouchi, Eriko Tokunaga, Kenichi Taguchi, Taito Esaki, Susumu Eguchi, Shinji Ohno |
| Abstract |
The roles of aromatase inhibitors (AIs) and luteinizing hormone-releasing hormone (LH-RH) agonists in the management of male breast cancer remain uncertain, with no reports in Japanese men. We report four Japanese male patients with metastatic breast cancer treated with AIs with or without an LH-RH agonist, and consider the relationship between treatment effect and estradiol (E2) concentration. Three patients were initially treated with AI alone after selective estrogen receptor modulators (SERMs), and one received AIs plus an LH-RH agonist after a SERM. Two patients treated with an AI alone responded, one patient with E2 levels below the lower assay limit and the other with levels above the limit. The other treated with an AI alone experienced progression regardless of the E2 levels below the lower assay limit, however, responded after the addition of an LH-RH agonist. E2 concentrations were related to the efficacy of treatment in one patient. The patient initially treated with an AI plus an LH-RH agonist also responded. No grade 3 or 4 adverse events were observed in any of the patients treated with AIs with or without an LH-RH agonist. AIs with or without an LH-RH agonist offer an effective treatment option for hormone receptor-positive metastatic male breast cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 15% |
| Student > Postgraduate | 4 | 15% |
| Researcher | 4 | 15% |
| Other | 3 | 11% |
| Student > Doctoral Student | 3 | 11% |
| Other | 3 | 11% |
| Unknown | 6 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 37% |
| Psychology | 4 | 15% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Arts and Humanities | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 9 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2016.
All research outputs
#16,272,032
of 23,975,976 outputs
Outputs from Breast Cancer
#303
of 614 outputs
Outputs of similar age
#245,491
of 410,028 outputs
Outputs of similar age from Breast Cancer
#8
of 21 outputs
Altmetric has tracked 23,975,976 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 614 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 410,028 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.